Previous 10 | Next 10 |
2024-01-24 08:40:30 ET Losers: Theratechnologies THTX -30% says FDA rejected new Egrifta version . Annovis Bio ( ANVS ) -11% refines timeline for Parkinson’s phase III study data announcement . BlackBerry Ltd BB -11% announces proposed private ...
MALVERN, Pa., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, has announced a postponement in the Phase III study data release for buntanetap in Parkinson’s Disease. This adj...
2024-01-20 10:00:00 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings r...
2024-01-20 01:54:32 ET Summary Annovis Bio has two upcoming major catalysts, a phase 2/3 AD clinical trial and a phase 3 PD clinical trial. The investigational drug, Buntanetap, is an enantiomer of a molecule previously tested for AD, with no success. We believe that the likel...
2024-01-19 15:00:29 ET More on the markets SPY Is At Its Highest Risk Level (Technical Analysis) Recession Forecasting: Indicators That Actually Help Your Portfolio (Part 3) New Secular Bull Markets Hidden In Plain Sight Investors retract capital from the fun...
2024-01-06 02:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-05 12:31:54 ET Gainers: Revelstone Capital Acquisition Corp ( RCAC ) +90% . Ainos ( AIMD ) +72% . Banzai International ( BNZI ) +62% . Safe and Green Development ( SGD ) +41% . Swvl Holdings ( SWVL ) +41% . Zoomcar Ho...
BERWYN, Pa., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) today announced its Founder, President and CE...
BERWYN, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase III study of its lead candidate buntanetap in patients with ...
2023-12-05 03:58:10 ET Summary Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anav...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio Inc. Company Name:
ANVS Stock Symbol:
OTCMKTS Market:
2024-05-17 06:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, provided updates from across the organization and announced fir...
MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its ...